Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.67B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$1.58B |
| 3 |
TE Connectivity
TEL
|
+$948M |
| 4 |
Tesla
TSLA
|
+$910M |
| 5 |
Boeing
BA
|
+$829M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Dynamics
GD
|
+$1.7B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Visa
V
|
+$1.5B |
| 4 |
Morgan Stanley
MS
|
+$1.27B |
| 5 |
Exelon
EXC
|
+$1.19B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.17% |
| 2 | Healthcare | 17.88% |
| 3 | Financials | 14.68% |
| 4 | Consumer Discretionary | 10.11% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
Lexicon Pharmaceuticals
LXRX
$1.11B
| $552K | ﹤0.01% |
747,996
+15,249
| +2% | +$18.4K |
|
1727
iShares MSCI Canada ETF
EWC
$6.19B
| $550K | ﹤0.01% |
13,640
+3,163
| +30% | +$132K |
|
1728
Aurinia Pharmaceuticals
AUPH
$1.92B
| $546K | ﹤0.01% |
+60,751
| New | +$496K |
|
1729
Ardelyx
ARDX
$1.24B
| $544K | ﹤0.01% |
107,345
-10,925
| -9% | -$60.4K |
|
1730
Elastic
ESTC
$7.39B
| $536K | ﹤0.01% |
5,414
-3,720
| -41% | -$344K |
|
1731
Abeona Therapeutics
ABEO
$389M
| $520K | ﹤0.01% |
+93,289
| New | +$574K |
|
1732
Novavax
NVAX
$1.26B
| $519K | ﹤0.01% |
64,538
-8,577
| -12% | -$82.7K |
|
1733
Lexeo Therapeutics
LXEO
$346M
| $507K | ﹤0.01% |
76,981
+25,089
| +48% | +$198K |
|
1734
Jack Henry & Associates
JKHY
$11.1B
| $506K | ﹤0.01% |
2,886
+423
| +17% | +$75.6K |
|
1735
ADC Therapeutics
ADCT
$140M
| $504K | ﹤0.01% |
253,342
+84,785
| +50% | +$222K |
|
1736
Solid Biosciences
SLDB
$849M
| $498K | ﹤0.01% |
124,551
+4,747
| +4% | +$26.1K |
|
1737
Neurogene
NGNE
$686M
| $496K | ﹤0.01% |
21,717
+3,427
| +19% | +$128K |
|
1738
Organon & Co
OGN
$3.56B
| $492K | ﹤0.01% |
32,966
+10,108
| +44% | +$165K |
|
1739
BioMarin Pharmaceuticals
BMRN
$11.7B
| $490K | ﹤0.01% |
7,461
+402
| +6% | +$26.9K |
|
1740
Best Buy
BBY
$18.2B
| $488K | ﹤0.01% |
5,683
+3,354
| +144% | +$306K |
|
1741
Nektar Therapeutics
NKTR
$2.46B
| $486K | ﹤0.01% |
34,827
+3,288
| +10% | +$58K |
|
1742
Henry Schein
HSIC
$10.2B
| $478K | ﹤0.01% |
6,902
+775
| +13% | +$55.7K |
|
1743
Black Diamond Therapeutics
BDTX
$102M
| $473K | ﹤0.01% |
221,236
+16,279
| +8% | +$46.7K |
|
1744
Royalty Pharma
RPRX
$25.5B
| $473K | ﹤0.01% |
18,539
+733
| +4% | +$19.4K |
|
1745
Arrow Electronics
ARW
$11.6B
| $464K | ﹤0.01% |
4,100
+168
| +4% | +$20.7K |
|
1746
Larimar Therapeutics
LRMR
$427M
| $449K | ﹤0.01% |
116,067
+10,821
| +10% | +$71.4K |
|
1747
PUT
Applovin
APP
$141B
| $440K | ﹤0.01% |
+110
| New | +$27.8K |
|
|
PPLI
1748
People Inc
PPLI
$3.45B
| $439K | ﹤0.01% |
+12,412
| New | +$497K |
|
1749
Carlyle Group
CG
$18.2B
| $437K | ﹤0.01% |
8,664
+344
| +4% | +$17.4K |
|
1750
FirstEnergy
FE
$27.9B
| $435K | ﹤0.01% |
10,929
-835
| -7% | -$34.9K |
|
Similar funds
Wellington Management Group's Q4 2024 Portfolio in Review
As of Q4 2024, Wellington Management Group held 2,066 positions worth $546B, down 4.3% from $571B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Wellington Management Group withdrew a net $25.7B in Q4 2024, closing 139 positions and reducing 894 holdings. Its most notable exit was Lineage Inc, an estimated $266M position sold in full.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Wellington Management Group opened a new position in TE Connectivity worth $910M.
- Wellington Management Group's largest Q4 2024 buy was TE Connectivity: 6,362,160 shares worth $910M.
- Wellington Management Group added most to Eli Lilly in Q4 2024, an estimated $1.67B increase.
- Wellington Management Group's biggest Q4 2024 reduction was General Dynamics, cutting an estimated $1.7B.
- Wellington Management Group fully exited Lineage Inc in Q4 2024, selling an estimated $266M.
- Wellington Management Group's ten largest holdings make up 25% of its $546B portfolio in Q4 2024.
- Wellington Management Group opened 161 new positions and closed 139 in Q4 2024.
- Wellington Management Group's portfolio value fell 4.3% quarter-over-quarter to $546B.
Based on Wellington Management Group's 13F filing for Q4 2024, filed 12 Feb 2025.